公开(公告)号：EP3329937A1

公开(公告)日：2018-06-06

申请号：EP16002576.3

申请日：2016-12-05

申请人： OGD2 Pharma ,  Université de Nantes ,  Centre National de la Recherche Scientifique CNRS ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Institut de Cancérologie de l'Ouest (I.C.O)

发明人： BIRKLE, Stéphane ,  FLEURENCE, Julien ,  FARAJ, Sébastien ,  LE DOUSSAL, Jean-Marc ,  COCHONNEAU, Denis ,  TERME, Mickaël ,  ASSOULINE, Brigitte

IPC分类号： A61K39/395 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/3084 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73

摘要： The present disclosure relates to a composition for delivery of an anti-cancer agent into a cell, expressing the OAcGD2 ganglioside comprising:
(i) at least one anti-cancer agent, and
(ii) at least one antibody recognizing the OAcGD2 ganglioside, wherein the at least one antibody recognizing the OAcGD2 ganglioside enhances the uptake of the at least one anti-cancer agent by the tumor cell. The antibody is known and is named the 8B6 antibody. Several variants of the variable claimed, including consensus sequences. Experimental results are provided for a limited number of anti-cancer agents (topotecan, doxorubicin, temozolomide).
Combined therapy with said agents show a more potent anti-tumor efficacy.

公开(公告)号：EP3548085A1

公开(公告)日：2019-10-09

申请号：EP17829598.6

申请日：2017-12-05

申请人： OGD2 Pharma ,  Université de Nantes ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Institut de Cancerologie de l'Ouest

发明人： BIRKLE, Stéphane ,  FLEURENCE, Julien ,  FARAJ, Sébastien ,  LE DOUSSAL, Jean-Marc ,  COCHONNEAU, Denis ,  TERME, Mickaël ,  ASSOULINE, Brigitte

IPC分类号： A61K39/395 ,  C07K16/30 ,  A61K39/00

公开(公告)号：EP4322937A1

公开(公告)日：2024-02-21

申请号：EP22717412.5

申请日：2022-04-13

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  OGD2 Pharma ,  Nantes Université

发明人： BIRKLE, Stéphane ,  VERMEULEN, Sarah ,  FOUGERAY, Sophie ,  BAHRI, Meriem ,  MADURA, Emilie ,  LE DOUSSAL, Jean-Marc

IPC分类号： A61K31/203 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00 ,  A61P35/04 ,  C07K16/28 ,  C07K16/30

公开(公告)号：EP4322938A1

公开(公告)日：2024-02-21

申请号：EP22717413.3

申请日：2022-04-13

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Nantes Université ,  OGD2 Pharma

发明人： BIRKLE, Stéphane ,  BAHRI, Meriem ,  FOUGERAY, Sophie ,  LE DOUSSAL, Jean-Marc ,  MADURA, Emilie

IPC分类号： A61K31/203 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30

公开(公告)号：EP2992018B1

公开(公告)日：2019-02-13

申请号：EP14723706.9

申请日：2014-04-29

申请人： OGD2 Pharma ,  Université de Nantes

发明人： BIRKLE, Stéphane ,  COCHONNEAU, Denis ,  DORVILLIUS, Mylène ,  LE DOUSSAL, Jean-Marc ,  TERME, Mickaël

IPC分类号： A61K39/00 ,  A61N5/10 ,  A61K39/395 ,  A61K45/06

公开(公告)号：EP2992018A1

公开(公告)日：2016-03-09

申请号：EP14723706.9

申请日：2014-04-29

申请人： OGD2 Pharma ,  Université de Nantes

发明人： BIRKLE, Stéphane ,  COCHONNEAU, Denis ,  DORVILLIUS, Mylène ,  LE DOUSSAL, Jean-Marc ,  TERME, Mickaël

IPC分类号： C07K16/30

CPC分类号： C07K16/3084 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73

摘要： An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.

摘要翻译： 识别用于治疗癌干细胞（CSC）癌症的O-乙酰化GD2神经节苷脂的抗体，包含用于治疗CSC癌症的抗体的药物组合物和在有需要的患者中治疗CSC癌症的方法，所述方法 包括向患者施用抗体。 还描述了用于诊断CSC的方法，使用O-乙酰化GD2神经节苷脂作为CSC癌症的生物标志物，以及预测受CSC癌症影响的受试者对抗体或组合物治疗的反应的方法 。

公开(公告)号：EP2076542B1

公开(公告)日：2012-08-15

申请号：EP07821118.2

申请日：2007-10-10

申请人： Université de Nantes

发明人： BIRKLE, Stéphane ,  MUSSINI, Jean-Marie ,  AUBRY, Jacques ,  BARBET, Jacques ,  CHATAL, Jean-François ,  MEZAZIGH HAMI, Assia ,  SUPIOT, Stéphane

IPC分类号： C07K16/30 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08 ,  G01N33/577 ,  G01N33/574 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00

CPC分类号： C07K16/3084 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

公开(公告)号：EP2076542A1

公开(公告)日：2009-07-08

申请号：EP07821118.2

申请日：2007-10-10

申请人： Université de Nantes

发明人： BIRKLE, Stéphane ,  MUSSINI, Jean-Marie ,  AUBRY, Jacques ,  BARBET, Jacques ,  CHATAL, Jean-François

IPC分类号： C07K16/30 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08 ,  G01N33/577 ,  G01N33/574 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00

CPC分类号： C07K16/3084 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.